Centennial Wealth Advisory’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.15M Buy
47,757
+2,320
+5% +$60.7K 0.25% 57
2026
Q1
$1.28M Buy
45,437
+6,212
+16% +$165K 0.31% 45
2025
Q4
$977K Buy
39,225
+1,161
+3% +$29.3K 0.26% 51
2025
Q3
$970K Buy
38,064
+2,219
+6% +$54.8K 0.27% 52
2025
Q2
$869K Buy
35,845
+13,815
+63% +$322K 0.28% 50
2025
Q1
$558K Sell
22,030
-2,588
-11% -$67.7K 0.2% 64
2024
Q4
$653K Buy
24,618
+2,490
+11% +$67.5K 0.26% 49
2024
Q3
$640K Buy
22,128
+4,149
+23% +$121K 0.25% 44
2024
Q2
$503K Buy
17,979
+8,239
+85% +$227K 0.22% 60
2024
Q1
$270K Sell
9,740
-1,896
-16% -$52.6K 0.13% 107
2023
Q4
$335K Sell
11,636
-64
-0.5% -$1.94K 0.17% 90
2023
Q3
$388K Sell
11,700
-1,600
-12% -$56.6K 0.21% 74
2023
Q2
$488K Buy
+13,300
New +$518K 0.25% 57
2022
Q3
Sell
-6,055
Closed -$317K 128
2022
Q2
$317K Buy
+6,055
New +$309K 0.18% 76

Other funds holding PFE

Centennial Wealth Advisory's PFE Position: Q2 2026 in Review

Centennial Wealth Advisory increased its Pfizer (PFE) stake by 5.1% in Q2 2026, buying an estimated $60.7K and bringing the position to 47,757 shares worth $1.15M. The position accounts for 0.25% of the portfolio, ranked #57.

Centennial Wealth Advisory first reported a position in PFE in Q2 2022 and has held it in 14 quarters since. The position peaked at $1.28M in Q1 2026. 491 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Centennial Wealth Advisory held 47,757 shares of Pfizer worth $1.15M as of Q2 2026.
  • Centennial Wealth Advisory bought 2,320 Pfizer shares in Q2 2026, an estimated $60.7K.
  • Pfizer made up 0.25% of Centennial Wealth Advisory's portfolio in Q2 2026, its #57 holding.
  • Centennial Wealth Advisory first reported a position in Pfizer in Q2 2022 and has held it in 14 quarters since.
  • Centennial Wealth Advisory's Pfizer position peaked at $1.28M in Q1 2026.
  • 491 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Centennial Wealth Advisory's 13F filing for Q2 2026, filed 13 Jul 2026.